Latest Conference Articles

Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times Europe® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community

2-year YOSEMITE and RHINE results show faricimab reduces treatment burden in patients with DMO

2-year YOSEMITE and RHINE results show faricimab reduces treatment burden in patients with DMO

May 5th 2022, 12:06pm

ARVO

Dr Jennifer I. Lim reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular oedema.

Testing spectacle lenses for myopia control in relation to changes in axial length

Testing spectacle lenses for myopia control in relation to changes in axial length

May 4th 2022, 12:32pm

ARVO

Dr Eva Chamorro points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.

Predicting metastasis with novel prognostic liquid biopsy for uveal melanoma

Predicting metastasis with novel prognostic liquid biopsy for uveal melanoma

May 4th 2022, 7:38am

ARVO

Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.

Diabetic rats protected from macular oedema hallmarks with THR-687 treatment

Diabetic rats protected from macular oedema hallmarks with THR-687 treatment

May 3rd 2022, 6:47pm

ARVO

THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.

Tackling today’s top challenges of clinical research

Tackling today’s top challenges of clinical research

May 3rd 2022, 2:10pm

ARVO

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

Investigators examine long-term effects of anti-VEGF injection on renal function

Investigators examine long-term effects of anti-VEGF injection on renal function

May 3rd 2022, 8:10am

ARVO

The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.

Relationship between dry eye disease and high myopia in teenagers investigated in study

Relationship between dry eye disease and high myopia in teenagers investigated in study

May 3rd 2022, 7:02am

ARVO

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Dr Osama Ibrahim Hirayama and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.

Unpacking the need to accelerate clinical studies in retina

Unpacking the need to accelerate clinical studies in retina

May 2nd 2022, 2:36pm

ARVO

Dr David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

Sealing masks to skin with tape may decrease risk of ocular surface damage during the COVID-19 pandemic

Sealing masks to skin with tape may decrease risk of ocular surface damage during the COVID-19 pandemic

May 2nd 2022, 11:32am

ARVO

During a presentation at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Dr Yuichi Hori and colleagues found that taping the top border of a surgical mask to a clinicians’ skin reduces the potential for ocular surface damage resulting from expirations of air reaching the ocular surface during the COVID-19 pandemic.

Injectable axitinib intravitreal implant delivers high drug levels to retinal tissue

Injectable axitinib intravitreal implant delivers high drug levels to retinal tissue

May 2nd 2022, 10:15am

ARVO

The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.